Abbott Receives FDA Approval For SIMCOR® (Niaspan® / Simvastatin), A Novel Combination Medicine For Comprehensive Cholesterol Management
Abbott received U.S. Food and Drug Administration (FDA) approval for SIMCOR®, the first fixed-dose combination of two widely prescribed cholesterol therapies, Niaspan® (Abbott’s proprietary niacin extended-release) and simvastatin.
Original post by Dentistry News From Medical News Today
Related Articles
Abbott Receives FDA Approval For SIMCOR(R) (Niaspan(R) / Simvastatin), A Novel Combination Medicine For Comprehensive Cholesterol Management Abbott’s Investigational SIMCOR® Offers Comparable LDL Lowering To Simvastatin And Significantly Raises HDL And Lowers Triglycerides In Phase III Lupin Receives US FDA Approval For Simvastatin Tablets Abbott Receives Supplemental FDA Approval For Its Best-in- course In Sensitivity RealTime HIV-1 Viral Load Test FDA Issues Early Communication About An Ongoing Review Of Vytorin
No comments yet. Be the first.
Leave a reply
